硝苯地平和罗钙全对尿毒症患者甲状旁腺素受体基因表达的影响  

Effects of nifedipine and calcitriol on the PTH/PTHrP receptor mRNA expression in uremic patients

作　　者：陈靖[1] 顾勇[1] 张健[1] 朱蔚钰 林善锬[1] 

机构地区：[1]上海医科大学华山医院肾内科,200040

出　　处：《中华肾脏病杂志》2000年第5期287-290,共4页Chinese Journal of Nephrology

基　　金：卫生部基金!(96-2-127)

摘　　要：目的观察钙通道阻滞剂硝苯地平和活性维生素 Ｄ制剂罗钙全对尿毒症患者外周血单个核细胞（ＰＢＭＣ）上甲状旁腺素（ＰＴＨ）受体基因表达的影响。方法３０例非糖尿病常规血液透析患者随机分成硝苯地平组、罗钙全组和安慰剂组，治疗８周。应用逆转录－聚合酶链反应（ＲＴ－ＰＣＲ）方法检测用药前后ＰＢＭＣ上ＰＴＨ受体ｍＲＮＡ表达。结果硝苯地平治疗能使尿毒症患者ＰＢＭＣ上ＰＴＨ受体＜ｍＲＮＡ的低表达显著上调（０．１４３６±０．０５００比０ ３５８４±０．０４００，Ｐ＜０． ００１），但仍未达到正常组水平（０．６８３７±０．０３００，Ｐ＜０．００１）。罗钙全治疗可明显纠正低钙、高磷和高ＰＴＨ血症，对ＰＴＨ受体ｍＲＮＡ表达也有一定上调作用（０．１４７２±０．０１００比０．２１９２±０．０２００，Ｐ＜０．００１）。结论硝苯地平和罗钙全均能部分纠正尿毒症患者ＰＴＨ受体基因表达的异常。Objective To investigate the effects of calcium channel blocker (nifedipine)and 1, 25 (OH) 2VitD3 (calcitriol) on the mRNA expression of PTH receptor in PBMC of uremic patients. Methods Thirty non-diabetic uremic patients undergoing maintenance hemodialysis were divided into the following groups: (1) nifedipine group; (2) calcitriol group; (3) placebo group. The level of PTH receptor mRNA was measured by semi-quantitative RT-PCR method at the end of 8th week. Results The down-regulation of PTH receptor in PBMC was observed in all patients before treatment, and there was no difference among three groups. After 8-week treatment, the levels of PTH receptor mRNA expression(PTH receptor I. O. D/ beta-actin I. O. D) were significantly increased in nifedipine group(from 0. 1436 ± 0. 0500 to 0. 3584 ± 0. 0400, P < 0. 001 ) and in calcitriol group(from 0. 1472 ± 0. 0100 to 0. 2192 ± 0. 0200, P < 0. 001 ), but still lower than that in normal group(0. 6837 ± 0. 0300, P < 0. 001 ). Placebo therapy produced no change. Conclusion Both calcium channel blocker and 1, 25 (OH) 2VitD3 could up-regulate PTH receptor mRNA expression in PBMC of uremic patients.

关 键 词：尿毒症 受体 甲状旁腺素 硝苯地平 罗钙全 

分 类 号：R692.5[医药卫生—泌尿科学]